VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 19,700 Progyny, Inc. $PGNY

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Progyny, Inc. (NASDAQ:PGNY) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 19,700 shares of the company’s stock, valued at approximately $433,000.

Other institutional investors have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Progyny in the 1st quarter worth approximately $354,000. GAMMA Investing LLC grew its position in shares of Progyny by 233.9% in the 1st quarter. GAMMA Investing LLC now owns 5,379 shares of the company’s stock worth $120,000 after buying an additional 3,768 shares during the last quarter. Oppenheimer Asset Management Inc. grew its position in shares of Progyny by 18.7% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 34,675 shares of the company’s stock worth $775,000 after buying an additional 5,459 shares during the last quarter. Voya Investment Management LLC grew its position in shares of Progyny by 258.2% in the 1st quarter. Voya Investment Management LLC now owns 185,495 shares of the company’s stock worth $4,144,000 after buying an additional 133,703 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Progyny by 0.6% in the 2nd quarter. Nordea Investment Management AB now owns 183,362 shares of the company’s stock worth $4,052,000 after buying an additional 1,140 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Trading Down 0.1%

Shares of NASDAQ PGNY opened at $19.49 on Friday. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $26.76. The company has a 50 day simple moving average of $21.71 and a two-hundred day simple moving average of $22.04. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of 33.03, a PEG ratio of 1.66 and a beta of 1.34.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The business had revenue of $332.87 million for the quarter, compared to analyst estimates of $315.70 million. During the same quarter in the previous year, the firm posted $0.17 earnings per share. The business’s revenue was up 9.5% on a year-over-year basis. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Analysts forecast that Progyny, Inc. will post 0.6 EPS for the current year.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of analyst reports. Raymond James Financial set a $28.00 price objective on shares of Progyny in a research report on Friday, August 8th. Truist Financial lifted their price objective on shares of Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research report on Thursday, July 17th. Leerink Partnrs raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 8th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Finally, Canaccord Genuity Group boosted their target price on shares of Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.44.

Insider Buying and Selling at Progyny

In related news, EVP Allison Swartz sold 2,398 shares of the business’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the transaction, the executive vice president directly owned 79,697 shares in the company, valued at $1,829,843.12. The trade was a 2.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kevin K. Gordon sold 2,500 shares of the business’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the completion of the transaction, the director owned 12,501 shares of the company’s stock, valued at approximately $275,522.04. This represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 7,895 shares of company stock valued at $179,311. Company insiders own 9.40% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.